Savara Inc.
Clinical trials sponsored by Savara Inc., explained in plain language.
A biopharmaceutical company developing inhaled therapies for rare respiratory diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New hope for kids with rare lung condition: inhaled protein therapy in trial Results expected Jun 2027 (estimated)
-
New hope for rare lung disease: investigational drug now available through expanded access
Disease control Expanded accessThis program offers adults with autoimmune pulmonary alveolar proteinosis (aPAP) access to an investigational inhaled medication called molgramostim. aPAP is a rare lung condition where surfactant builds up, making breathing difficult. The drug aims to help the lungs clear this b…
Sponsor: Savara Inc. • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
New hope for kids with rare lung condition: inhaled protein therapy in trial
Disease control Recruiting nowThis study tests an inhaled drug called molgramostim in children aged 6 to 18 with autoimmune pulmonary alveolar proteinosis (aPAP), a rare disease where protein builds up in the lungs and makes breathing hard. All 5 participants will take the drug daily via a nebulizer for 12 mo…
Phase 3 • Sponsor: Savara Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC